MedicalResearch.com Interview with:
[caption id="attachment_72890" align="alignleft" width="195"]

Dr. Jay Solgama[/caption]
Jay P. Solgama, MD
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton, PA
MedicalResearch.com: What is the background for this study?
Response: The United States (U.S.) continues to face a severe opioid crisis, with nearly 80,000 opioid-related deaths reported in 2023. Prescription opioids play a central role in this epidemic, with a large proportion of misuse involving commonly prescribed pain relievers such as oxycodone. Prior research has shown that oxycodone (brand names OxyContin, Roxicodone, OxyIR, RoxyBond, and Percocet) is one of the most widely consumed and misused opioids in the U.S., with notable geographic variation in its distribution across states [1–3].
Against this backdrop, the present study aimed to comprehensively characterize oxycodone distribution across the U.S. from 2000 to 2023. Using three complementary data sources—the Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System (ARCOS), Medicaid State Drug Utilization Data (M-SDUD), and the Medicare Part D Prescribers dataset (M-PDP)—we sought to evaluate national and state-level patterns, as well as identify strengths and weaknesses of each dataset [4,5]. The Medicaid program serves low-income and Medicare serves elderly patients.